Karuna Therapeutics, Inc.

Over the last four quarters, Karuna Therapeutics, Inc. achieved steady financial progress, growing revenue from $654000.00 in Q1 2023 to $0.00 in Q4 2023. Gross profit stayed firm with margins at N/A in Q4 2023 versus 50% in Q1 2023. Operating income totaled -$129.59M in Q4 2023, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$129.14M. Net income rose to -$113.82M, with EPS at -$3.01. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.